Some elements of our website may not load if you have an ad blocker turned on.

Forrest General Hospital first to use FDA-approved Drug Coated Balloon for Peripheral Arterial Disease - Forrest Health
    Share This
    Skip to main content

    Published on November 12, 2014

    Forrest General Hospital first to use FDA-approved Drug Coated Balloon for Peripheral Arterial Disease

    HATTIESBURG, Miss. – (November 12, 2014) Forrest General is now using a new treatment for peripheral arterial disease (PAD), a disease in which plaque builds up in the arteries that carry blood to the head, organs and limbs, creating blockages. This treatment – the Lutonix® 035 Drug Coated Balloon PTA Catheter (DCB) – is the first and only treatment of its kind approved by the U.S. Food and Drug Administration (FDA).


    “We are committed to bringing innovations in care to our patients, and we are excited to be the first hospital in Hattiesburg, Mississippi to use this new treatment option,” said Joe Marcello, Forrest General Heart and Vascular service line administrator. “The Lutonix ® 035 DCB is a new first-line therapy for treating blockages without closing the door to other treatment options down the road, an important consideration as we help our patients manage this painful, progressive and debilitating disease.”


    Millions of Americans suffer from PAD in the femoral artery and Forrest General treats hundreds of these patients each year. If untreated, PAD can lead to critical limb ischemia (CLI), a severe blockage in the arteries of the legs or feet, and eventually, even amputation.2 Recent data shows the majority of all leg and foot amputations in the U.S. are due to vascular disease, including PAD.3


    Successful treatment of PAD requires improved blood flow (patency) for longer periods of time. Developed by C.R. Bard, the Lutonix® 035 DCB uniquely combines an angioplasty balloon coated with a low dose of Paclitaxel to improve blood flow in blocked vessels above the knee.


    Currently, minimally-invasive procedures such as angioplasty balloons, stents, atherectomy, medications and vascular bypass surgery are some of the accepted ways to treat PAD, but these options may be limited depending on the type of arterial blockage. The Lutonix® 035 DCB is a safe and effective addition to the treatment algorithm for PAD in the femoral artery.


    If you or someone you know have symptoms of PAD, a physician should be seen without delay.


    Forrest General has also partnered with the Hattiesburg Clinic Vascular Surgeons to offer Dare to C.A.R.E., a FREE comprehensive cardiovascular disease early detection and education program that is offered to qualifying men and women in the Pine Belt.


    Residents have an opportunity to receive a free screening for PAD at Forrest General. Anyone over age 60 or over age 50 with risk factors such as smoking, diabetes, high blood pressure or high cholesterol, can qualify for this screening. The screening includes a non-invasive ultrasound of the carotid arteries in the neck, the aorta in the abdomen and an evaluation of leg circulation.


    To learn more about PAD or Dare to C.A.R.E., call FGH OnCall at 1-800-844-4445

    Media Contact

    All media related inquiries should be directed to Amanda Kirby, Media Coordinator, by email or phone at 601-288-1303.

    Related Locations